Comparison of the Antifibrotic Efficacy of the Pan-Histone Deacetylase-Inhibitor Panobinostat Versus the IPF-Drug Pirfenidone in Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis

被引：0
|
作者：
Korfei, M. [1 ,2 ]
Stelmaszek, D. [1 ,2 ]
Skwarna, S. [1 ,2 ]
Chillappagari, S. [1 ,2 ]
Bach, A. C. [1 ,2 ]
MacKenzie, B. [1 ,2 ]
Ruppert, C. [1 ,2 ]
Saito, S. [3 ]
Mahavadi, P. [1 ,2 ]
Klepetko, W. [4 ]
Fink, L. [5 ]
Seeger, W. [1 ,6 ]
Lasky, J. A. [3 ]
Pullamsetti, S. S. [7 ]
Kraemer, O. [8 ]
Guenther, A. [1 ,2 ]
机构：
[1] Justus Liebig Univ Giessen, German Ctr Lung Res DZL, Dept Internal Med, Giessen, Germany
[2] Justus Liebig Univ Giessen, German Ctr Lung Res DZL, Biomed Res Ctr Seltersberg BFS, Giessen, Germany
[3] Tulane Univ, Hlth Sci Ctr, Pulm Dis Sect, Dept Med, New Orleans, LA 70118 USA
[4] Vienna Gen Hosp, Dept Thorac Surg, Vienna, Austria
[5] Justus Liebig Univ Giessen, German Ctr Lung Res DZL, Inst Pathol & Cytol Wetzlar, Giessen, Germany
[6] Justus Liebig Univ Giessen, German Ctr Lung Res DZL, ECCPS, Giessen, Germany
[7] Justus Liebig Univ Giessen, German Ctr Lung Res DZL, Max Planck Inst Heart & Lung Res Bad Nauheim, Giessen, Germany
[8] Univ Med Ctr, Dept Toxicol, Mainz, Germany
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A5751
引用
收藏
页数：2
相关论文
共 8 条
  • [1] Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
    Korfei, Martina
    Stelmaszek, Daniel
    MacKenzie, BreAnne
    Skwarna, Sylwia
    Chillappagari, Shashipavan
    Bach, Anna C.
    Ruppert, Clemens
    Saito, Shigeki
    Mahavadi, Poornima
    Klepetko, Walter
    Fink, Ludger
    Seeger, Werner
    Lasky, Joseph A.
    Pullamsetti, Soni S.
    Kraemer, Oliver H.
    Guenther, Andreas
    PLOS ONE, 2018, 13 (11):
  • [2] Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
    Korfei, Martina
    Skwarna, Sylwia
    Henneke, Ingrid
    Klymenko, Oleksiy
    Dahlem, Gabriele
    Ziegler, Susanna
    von der Beck, Daniel
    Klepetko, Walter
    Fink, Ludger
    Seeger, Werner
    Kramer, Oliver
    Guenther, Andreas
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [3] Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis Data from the IPF-PRO Registry
    Salisbury, Margaret L.
    Conoscenti, Craig S.
    Culver, Daniel A.
    Yow, Eric
    Neely, Megan L.
    Bender, Shaun
    Hartmann, Nadine
    Palmer, Scott M.
    Leonard, Thomas B.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (11) : 1413 - 1423
  • [4] EFFICACY OF PIRFENIDONE ON DYSPNEA IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): RESULTS FROM A POST HOC RESPONDER ANALYSIS
    Glassberg, Marilyn K.
    Thavarajah, Krishna
    Collins, Bridget F.
    Gupta, Sachin
    Trzaskoma, Benjamin
    Kirchgaessler, Klaus-Uwe
    Devine, Jacob
    Raghu, Ganesh
    CHEST, 2022, 162 (04) : 1246A - 1247A
  • [5] Spirotetrahydroisoquinoline-Based Histone Deacetylase Inhibitors as New Antifibrotic Agents: Biological Evaluation in Human Fibroblasts from Bronchoalveolar Lavages of Idiopathic Pulmonary Fibrosis Patients
    Fontana, Anna
    Bergantini, Laura
    Carullo, Gabriele
    Scalvini, Laura
    D'Alessandro, Miriana
    Papulino, Chiara
    Cameli, Paolo
    Gangi, Sara
    Vincenzi, Fabrizio
    Varani, Katia
    Contri, Chiara
    Pasquini, Silvia
    Pistocchi, Anna
    Pezzotta, Alex
    Carbone, Sabrina
    Saponara, Simona
    Gemma, Sandra
    Altucci, Lucia
    Benedetti, Rosaria
    Lodola, Alessio
    Mor, Marco
    Bargagli, Elena
    Butini, Stefania
    Campiani, Giuseppe
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024,
  • [6] No Relevant Pharmacokinetic Interaction Between Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Results from a Drug-Drug Interaction Study
    Richeldi, L.
    Fletcher, S.
    Adamali, H.
    Chaudhuri, N.
    Wiebe, S.
    Wind, S.
    Hohl, K.
    Baker, A.
    Schlenker-Herceg, R.
    Stowasser, S.
    Maher, T. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [7] Inhibition of Profibrotic Signaling in Primary Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis (IPF) by Sirtuin-1/-2-Inhibitor Sirtinol
    Korfei, M.
    Zlotkowski, J. V.
    Stelmaszek, D.
    Ruppert, C.
    Seeger, W.
    Guenther, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [8] Effect of Pirfenidone on All-Cause Mortality in Patients With Idiopathic Pulmonary Fibrosis (IPF): Comparison of Pooled Analysis With Meta-analysis From the ASCEND and CAPACITY Trials
    Nathan, Steven
    Albera, Carlo
    Bradford, Williamson
    Costabel, Ulrich
    Daigl, Monica
    Kirchgaessler, Klaus-Uwe
    Du Bois, Roland
    Glaspole, Ian
    Glassberg, Marilyn
    King, Talmadge
    Lancaster, Lisa
    Lederer, David
    Pereira, Carlos
    Swigris, Jeffrey
    Valeyre, Dominique
    Noble, Paul
    CHEST, 2015, 148 (04)
1